English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Staphylococcus aureus continues to pose a major threat to public health and is responsible for 20,000 deaths each year in the US [1]. The problem is exacerbated by methicillin-resistant S. aureus (MRSA) which, according to the World Health Organisation’s 2014 Antimicrobial Resistance Global Report on Surveillance is associated with a>60% increase in mortality compared to antibiotic susceptible S. aureus. Membrane transport systems can control both virulence and antibiotic resistance and represent novel targets for therapeutic agents. Here we discuss how efforts to overcome antimicrobial drug resistance could include novel agents targeting important metabolic processes dependent on membrane transporters, which have the potential to augment existing antibiotics.

Exploring amino acid and peptide transporters as therapeutic targets to attenuate virulence and antibiotic resistance in Staphylococcus aureus